GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of dual agonist — my 21-week log, condensed into one table — 39 comments in the full submission. View in context.
1.2k
c/survodutide·submitted 7 months ago by u/samir_falk

dual agonist — my 21-week log, condensed into one table

Questionbranch of 10 comments

I have had 5 orders now and I keep a table, so here is the honest summary rather than a vibe. Material has been consistent. Communication has not. Shipping has varied by about 14 days on nominally the same lane, which matters more in summer than in February. The independent number came back 97.9% against a claimed…

Read the full submission and all 39 comments →

This branch

10 comments, started 7 months ago
u/whois_wanda65 points·7 months ago

Not convinced. The evidence does not support that reading.

replysharereportpermalink
u/elin_tamm44 points·7 months ago

glucagon co-agonism has a different safety story

replysharereportpermalink
u/teodor_szabo18 points·7 months ago

Yeah, glucagon co-agonism is genuinely different.

replysharereportpermalink
u/diego_szabo9 points·7 months ago

the safety profile is not just tirzepatide amplified

replysharereportpermalink
u/chidi_demir17 points·7 months ago

the heart rate signal is real in the data

replysharereportpermalink
u/neha_rahimi5 points·7 months ago·edited

the heart rate signal is real in the data

Disagree on that part. 96.8% and 96.2% on the same vial is normal.

replysharereportpermalink
u/zeynep_ndiaye4 points·7 months ago

Strongly agree. The safety story is separate.

replysharereportpermalink
u/nora_ramos1 point·7 months ago

phase 22 data is interesting, phase 16 will be different

replysharereportpermalink
u/samir_falkOP25 points·7 months ago

Not convinced.

Disagree on that part. 99.2% and 98.9% on the same vial is normal.

replysharereportpermalink
u/sofia_ferreira17 points·7 months ago

Respectfully this is a sample of one presented as a finding.

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →